Unlike many other solid tumors where tumor-specific antigens are scarce, gliomas have 6 clinically validated CAR T antigens that, when targeted, demonstrated tumor regression and were found to be safe when administered locally (Table 2) These targets include IL13Rα2 (63–69), EGFRvIII (70–72), EGFR (71, 73–77), HER2 (64, 74, 78–81), B7-H3 (82–87), and GD2 (86, 88–91) (Figure 2, Table 2). This evidence concerns the gene ERBB2 and neoplasm.